Correction to: Psychometric Validation of the Autism Impact Measure (AIM) / R. HOUGHTON in Journal of Autism and Developmental Disorders, 49-6 (June 2019)  

Public ISBD [article]  inJournal of Autism and Developmental Disorders > 49-6 (June 2019) . - p.2571 Titre : Correction to: Psychometric Validation of the Autism Impact Measure (AIM) Type de document : Texte imprimé et/ou numérique Auteurs : R. HOUGHTON, Auteur ; B. MONZ, Auteur ; K. LAW, Auteur ; G. LOSS, Auteur ; S. LE SCOUILLER, Auteur ; F. DE VRIES, Auteur ; T. WILLGOSS, Auteur Article en page(s) : p.2571 Langues : Anglais (eng) Index. décimale : PER Périodiques Résumé : The article Psychometric Validation of the Autism Impact Measure (AIM), written by Richard Houghton, Brigitta Monz, Kiely Law, Georg Loss, Stephanie Le Scouiller, Frank de Vries and Tom Willgoss was originally published electronically on the publisher's internet portal (currently SpringerLink) on 09 April 2019 without open access.With the author(s)' decision to opt for Open Choice the copyright of the article changed on May 2019 to (c) The Author(s) 2019 and the article is forthwith distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits use, duplication, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license and indicate if changes were made. En ligne : https://dx.doi.org/10.1007/s10803-019-04076-z Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=400 [article] Correction to: Psychometric Validation of the Autism Impact Measure (AIM) [Texte imprimé et/ou numérique] / R. HOUGHTON, Auteur ; B. MONZ, Auteur ; K. LAW, Auteur ; G. LOSS, Auteur ; S. LE SCOUILLER, Auteur ; F. DE VRIES, Auteur ; T. WILLGOSS, Auteur . - p.2571. Langues : Anglais (eng) in Journal of Autism and Developmental Disorders > 49-6 (June 2019) . - p.2571 Index. décimale : PER Périodiques Résumé : The article Psychometric Validation of the Autism Impact Measure (AIM), written by Richard Houghton, Brigitta Monz, Kiely Law, Georg Loss, Stephanie Le Scouiller, Frank de Vries and Tom Willgoss was originally published electronically on the publisher's internet portal (currently SpringerLink) on 09 April 2019 without open access.With the author(s)' decision to opt for Open Choice the copyright of the article changed on May 2019 to (c) The Author(s) 2019 and the article is forthwith distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits use, duplication, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license and indicate if changes were made. En ligne : https://dx.doi.org/10.1007/s10803-019-04076-z Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=400

Epilepsy and Autism Severity: A Study of 6,975 Children / J. B. EWEN in Autism Research, 12-8 (August 2019)  

Public ISBD [article]  inAutism Research > 12-8 (August 2019) . - p.1251-1259 Titre : Epilepsy and Autism Severity: A Study of 6,975 Children Type de document : Texte imprimé et/ou numérique Auteurs : J. B. EWEN, Auteur ; A. R. MARVIN, Auteur ; K. LAW, Auteur ; P. H. LIPKIN, Auteur Article en page(s) : p.1251-1259 Langues : Anglais (eng) Mots-clés : effect size  epilepsy  regression  risk factor  severity Index. décimale : PER Périodiques Résumé : Epilepsy is known to occur in a higher-than-expected proportion of individuals with autism spectrum disorders (ASDs). Prior studies of this heterogeneous disorder have suggested that intelligence quotient (IQ) may drive this relationship. Because intellectual disability (ID) is, independently of ASD, a risk factor for epilepsy, current literature calls into question the long-understood unique relationship between ASD and epilepsy. Second, data have been unclear about whether developmental regression in ASD is associated with epilepsy. Using two cohorts from an online research registry, totaling 6,975 children with ASD, we examined the independent role of four ASD severity measures in driving the relationship with epilepsy: ID, language impairment, core ASD symptom severity, and motor dysfunction, controlling for two known relevant factors: age and sex. We also examined whether developmental regression and epilepsy have an independent statistical link. All four ASD severity factors showed independent statistical associations with epilepsy in one cohort, and three in the other. ID showed the largest relative risk (RR) in both cohorts. Effect sizes were modest. Regression similarly showed an independent statistical association with epilepsy, but with small effect size. Similar to previous work, ID showed the greatest contribution to RR for epilepsy among children with ASD. However, other ASD severity markers showed statistical associations, demonstrating that the ASD-epilepsy association is not reducible to the effect of ID. Inconsistencies in the literature may be due to underpowered studies, yet moving forward with larger-n studies, clinical significance and scientific relevance may be dictated by effect size and not merely statistical significance. Autism Res 2019, 12: 1251-1259. (c) 2019 International Society for Autism Research, Wiley Periodicals, Inc. LAY SUMMARY: Epilepsy is known to occur more often in individuals with autism spectrum disorders (ASDs) than is the case in the general population. The association between ASD and epilepsy is of interest because studying the two disorders in combination may help advance our understanding of genetic, molecular, and cellular mechanisms-as well as therapies-for both. Recent studies have suggested that intelligence quotient (IQ) alone in individuals with ASD may account for the increased prevalence of epilepsy. However, our approach was to look at a range of severity factors relevant to ASD and to look for correlations between each severity factor and epilepsy, within two large samples of children with ASD. In summary, we found that each severity factor-presence of intellectual disability, presence of language atypicalities, ASD-specific symptoms severity, and presence of motor issues-independently predicted a small increased risk for epilepsy, countering the argument that IQ alone is a risk factor. We also examined whether epilepsy is associated with developmental regression. Although severe epilepsy syndromes such as Landau-Kleffner syndrome are known to cause autistic-like symptoms following developmental regression, there is controversy about whether other forms of epilepsy are associated with the more common developmental regression seen in many young children with epilepsy. Indeed, we found a small association between epilepsy and developmental regression. En ligne : http://dx.doi.org/10.1002/aur.2132 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=405 [article] Epilepsy and Autism Severity: A Study of 6,975 Children [Texte imprimé et/ou numérique] / J. B. EWEN, Auteur ; A. R. MARVIN, Auteur ; K. LAW, Auteur ; P. H. LIPKIN, Auteur . - p.1251-1259. Langues : Anglais (eng) in Autism Research > 12-8 (August 2019) . - p.1251-1259 Mots-clés : effect size  epilepsy  regression  risk factor  severity Index. décimale : PER Périodiques Résumé : Epilepsy is known to occur in a higher-than-expected proportion of individuals with autism spectrum disorders (ASDs). Prior studies of this heterogeneous disorder have suggested that intelligence quotient (IQ) may drive this relationship. Because intellectual disability (ID) is, independently of ASD, a risk factor for epilepsy, current literature calls into question the long-understood unique relationship between ASD and epilepsy. Second, data have been unclear about whether developmental regression in ASD is associated with epilepsy. Using two cohorts from an online research registry, totaling 6,975 children with ASD, we examined the independent role of four ASD severity measures in driving the relationship with epilepsy: ID, language impairment, core ASD symptom severity, and motor dysfunction, controlling for two known relevant factors: age and sex. We also examined whether developmental regression and epilepsy have an independent statistical link. All four ASD severity factors showed independent statistical associations with epilepsy in one cohort, and three in the other. ID showed the largest relative risk (RR) in both cohorts. Effect sizes were modest. Regression similarly showed an independent statistical association with epilepsy, but with small effect size. Similar to previous work, ID showed the greatest contribution to RR for epilepsy among children with ASD. However, other ASD severity markers showed statistical associations, demonstrating that the ASD-epilepsy association is not reducible to the effect of ID. Inconsistencies in the literature may be due to underpowered studies, yet moving forward with larger-n studies, clinical significance and scientific relevance may be dictated by effect size and not merely statistical significance. Autism Res 2019, 12: 1251-1259. (c) 2019 International Society for Autism Research, Wiley Periodicals, Inc. LAY SUMMARY: Epilepsy is known to occur more often in individuals with autism spectrum disorders (ASDs) than is the case in the general population. The association between ASD and epilepsy is of interest because studying the two disorders in combination may help advance our understanding of genetic, molecular, and cellular mechanisms-as well as therapies-for both. Recent studies have suggested that intelligence quotient (IQ) alone in individuals with ASD may account for the increased prevalence of epilepsy. However, our approach was to look at a range of severity factors relevant to ASD and to look for correlations between each severity factor and epilepsy, within two large samples of children with ASD. In summary, we found that each severity factor-presence of intellectual disability, presence of language atypicalities, ASD-specific symptoms severity, and presence of motor issues-independently predicted a small increased risk for epilepsy, countering the argument that IQ alone is a risk factor. We also examined whether epilepsy is associated with developmental regression. Although severe epilepsy syndromes such as Landau-Kleffner syndrome are known to cause autistic-like symptoms following developmental regression, there is controversy about whether other forms of epilepsy are associated with the more common developmental regression seen in many young children with epilepsy. Indeed, we found a small association between epilepsy and developmental regression. En ligne : http://dx.doi.org/10.1002/aur.2132 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=405

Psychological distress among caregivers raising a child with autism spectrum disorder during the COVID-19 pandemic / L. G. KALB in Autism Research, 14-10 (October 2021)  

Public ISBD [article]  inAutism Research > 14-10 (October 2021) . - p.2183-2188 Titre : Psychological distress among caregivers raising a child with autism spectrum disorder during the COVID-19 pandemic Type de document : Texte imprimé et/ou numérique Auteurs : L. G. KALB, Auteur ; E. BADILLO-GOICOECHEA, Auteur ; C. HOLINGUE, Auteur ; K. E. RIEHM, Auteur ; J. THRUL, Auteur ; E. A. STUART, Auteur ; E. J. SMAIL, Auteur ; K. LAW, Auteur ; C. WHITE-LEHMAN, Auteur ; D. FALLIN, Auteur Article en page(s) : p.2183-2188 Langues : Anglais (eng) Mots-clés : Autism Spectrum Disorder/complications/epidemiology  Covid-19  Caregivers  Child  Humans  Pandemics  Parents  Psychological Distress  SARS-CoV-2  Stress, Psychological/complications/epidemiology  United States/epidemiology Index. décimale : PER Périodiques Résumé : The COVID-19 pandemic may disproportionately impact parents of children with autism spectrum disorder (ASD). Loss of services and supports, heightened fears about increased infection rates, and disruption of daily routines likely adversely affect the well-being of children with ASD and their families. The goal of this study was to examine differences in psychological distress-as defined by symptoms of anxiety, depression, loneliness, and hyperarousal-between parents raising a child with ASD and parents in the US as a whole during the early stages of the pandemic (March-April 2020). Parents raising a child with ASD (n = 3556) were recruited through SPARK, a national ASD research registry, whereas a representative sample of parents in the US (n = 5506) were recruited from the Pew Research Center's American Trends Panel. All data were captured via online surveys. Descriptive statistics and multivariable logistic regressions examined psychological distress at the item and summary score level. Parents of children with ASD reported higher levels of overall psychological distress (48% vs. 25%; aOR = 1.60, 95% CI: 1.32, 1.84, p? En ligne : http://dx.doi.org/10.1002/aur.2589 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=450 [article] Psychological distress among caregivers raising a child with autism spectrum disorder during the COVID-19 pandemic [Texte imprimé et/ou numérique] / L. G. KALB, Auteur ; E. BADILLO-GOICOECHEA, Auteur ; C. HOLINGUE, Auteur ; K. E. RIEHM, Auteur ; J. THRUL, Auteur ; E. A. STUART, Auteur ; E. J. SMAIL, Auteur ; K. LAW, Auteur ; C. WHITE-LEHMAN, Auteur ; D. FALLIN, Auteur . - p.2183-2188. Langues : Anglais (eng) in Autism Research > 14-10 (October 2021) . - p.2183-2188 Mots-clés : Autism Spectrum Disorder/complications/epidemiology  Covid-19  Caregivers  Child  Humans  Pandemics  Parents  Psychological Distress  SARS-CoV-2  Stress, Psychological/complications/epidemiology  United States/epidemiology Index. décimale : PER Périodiques Résumé : The COVID-19 pandemic may disproportionately impact parents of children with autism spectrum disorder (ASD). Loss of services and supports, heightened fears about increased infection rates, and disruption of daily routines likely adversely affect the well-being of children with ASD and their families. The goal of this study was to examine differences in psychological distress-as defined by symptoms of anxiety, depression, loneliness, and hyperarousal-between parents raising a child with ASD and parents in the US as a whole during the early stages of the pandemic (March-April 2020). Parents raising a child with ASD (n = 3556) were recruited through SPARK, a national ASD research registry, whereas a representative sample of parents in the US (n = 5506) were recruited from the Pew Research Center's American Trends Panel. All data were captured via online surveys. Descriptive statistics and multivariable logistic regressions examined psychological distress at the item and summary score level. Parents of children with ASD reported higher levels of overall psychological distress (48% vs. 25%; aOR = 1.60, 95% CI: 1.32, 1.84, p? En ligne : http://dx.doi.org/10.1002/aur.2589 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=450

Psychometric Validation of the Autism Impact Measure (AIM) / R. HOUGHTON in Journal of Autism and Developmental Disorders, 49-6 (June 2019)  

Public ISBD [article]  inJournal of Autism and Developmental Disorders > 49-6 (June 2019) . - p.2559-2570 Titre : Psychometric Validation of the Autism Impact Measure (AIM) Type de document : Texte imprimé et/ou numérique Auteurs : R. HOUGHTON, Auteur ; B. MONZ, Auteur ; K. LAW, Auteur ; G. LOSS, Auteur ; S. LE SCOUILLER, Auteur ; F. DE VRIES, Auteur ; T. WILLGOSS, Auteur Article en page(s) : p.2559-2570 Langues : Anglais (eng) Mots-clés : Autism spectrum disorder  Outcome  Psychometric validation  Symptoms  Treatment Index. décimale : PER Périodiques Résumé : The Autism impact measure (AIM) is a caregiver-reported questionnaire assessing autism symptom frequency and impact in children, previously shown to have good test-retest reliability, convergent validity and structural validity. This study extended previous work by exploring the AIM's ability to discriminate between 'known-groups' of children, and estimating thresholds for clinically important responses. Data were collected online and electronically on computer and mobile devices; hence, it was also possible to confirm other psychometric properties of the AIM in this format. This study provides confirmatory and additional psychometric validation of the AIM. The AIM offers a valid, quick and inexpensive method for caregivers to report core symptoms of autism spectrum disorder (ASD) including communication deficits, difficulties with social interactions and repetitive behaviors. En ligne : https://dx.doi.org/10.1007/s10803-019-04011-2 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=400 [article] Psychometric Validation of the Autism Impact Measure (AIM) [Texte imprimé et/ou numérique] / R. HOUGHTON, Auteur ; B. MONZ, Auteur ; K. LAW, Auteur ; G. LOSS, Auteur ; S. LE SCOUILLER, Auteur ; F. DE VRIES, Auteur ; T. WILLGOSS, Auteur . - p.2559-2570. Langues : Anglais (eng) in Journal of Autism and Developmental Disorders > 49-6 (June 2019) . - p.2559-2570 Mots-clés : Autism spectrum disorder  Outcome  Psychometric validation  Symptoms  Treatment Index. décimale : PER Périodiques Résumé : The Autism impact measure (AIM) is a caregiver-reported questionnaire assessing autism symptom frequency and impact in children, previously shown to have good test-retest reliability, convergent validity and structural validity. This study extended previous work by exploring the AIM's ability to discriminate between 'known-groups' of children, and estimating thresholds for clinically important responses. Data were collected online and electronically on computer and mobile devices; hence, it was also possible to confirm other psychometric properties of the AIM in this format. This study provides confirmatory and additional psychometric validation of the AIM. The AIM offers a valid, quick and inexpensive method for caregivers to report core symptoms of autism spectrum disorder (ASD) including communication deficits, difficulties with social interactions and repetitive behaviors. En ligne : https://dx.doi.org/10.1007/s10803-019-04011-2 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=400

Risperidone versus aripiprazole fracture risk in children and adolescents with autism spectrum disorders / R. HOUGHTON in Autism Research, 14-8 (August 2021)  

Public ISBD [article]  inAutism Research > 14-8 (August 2021) . - p.1800-1814 Titre : Risperidone versus aripiprazole fracture risk in children and adolescents with autism spectrum disorders Type de document : Texte imprimé et/ou numérique Auteurs : R. HOUGHTON, Auteur ; J. VAN DEN BERGH, Auteur ; K. LAW, Auteur ; Y. LIU, Auteur ; F. DE VRIES, Auteur Article en page(s) : p.1800-1814 Langues : Anglais (eng) Mots-clés : Adolescent  Antipsychotic Agents/adverse effects  Aripiprazole/adverse effects  Autism Spectrum Disorder/complications/drug therapy/epidemiology  Child  Cohort Studies  Female  Fractures, Bone/drug therapy/epidemiology  Humans  Male  Retrospective Studies  Risperidone/adverse effects  United States/epidemiology  antipsychotics  aripiprazole  autism spectrum disorder  fractures  risperidone Index. décimale : PER Périodiques Résumé : Risperidone and aripiprazole, commonly used antipsychotics in children with autism spectrum disorder (ASD), have previously been associated with elevated fracture risk in other populations. The aim of this study was to evaluate and compare the risk of fracture among children with ASD using risperidone or aripiprazole. This was a retrospective, propensity-score matched cohort study, set between January 2013 and December 2018. We used the MarketScan Medicaid insurance data, which covers multiple states of the United States. We included ASD children aged 2-18?years, who were new users of aripiprazole or risperidone and with no prior history of antipsychotic use or fractures. The main exposure was the continued use of aripiprazole or risperidone. The incidence rates of any fracture during follow-up were evaluated, and the risk between aripiprazole and risperidone was compared via Cox-proportional hazard models. Results were stratified by age, sex, duration of exposure and fracture site. In total, 3312 patients (78% male; mean [SD] age 11.0 [3.7] years) were identified for each cohort. Over the full duration of follow-up, fracture incidence rates per 1000 patient-years were 23.2 for risperidone and 38.4 for aripiprazole (hazard ratio and 95% confidence interval: 0.60 [0.44-0.83]). Risks were similar between cohorts throughout the first 180?days on treatment, but significantly higher in the aripiprazole group thereafter. Extremity fractures drove most of the increased risk, with the biggest differences in lower leg and ankle fractures. Differences widened for children aged 10?years or younger (HR [95% CI]: 0.47 [0.30-0.74]). In conclusion, compared to aripiprazole, risperidone was associated with 40% lower risk of fracture. Further analysis on the mechanism and long-term bone health of antipsychotic-treated children with ASD is warranted. LAY SUMMARY: We compared the risk of bone fractures among 6624 children with autism spectrum disorder (ASD), half of whom used risperidone and half of whom used aripiprazole. Taking other factors into account, risks were similar between the two groups throughout the first 180?days on treatment, but significantly higher in the aripiprazole group thereafter. The biggest differences were in lower leg and ankle fractures. Overall, compared with aripiprazole, risperidone was associated with 40% lower risk of fracture. En ligne : http://dx.doi.org/10.1002/aur.2541 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=449 [article] Risperidone versus aripiprazole fracture risk in children and adolescents with autism spectrum disorders [Texte imprimé et/ou numérique] / R. HOUGHTON, Auteur ; J. VAN DEN BERGH, Auteur ; K. LAW, Auteur ; Y. LIU, Auteur ; F. DE VRIES, Auteur . - p.1800-1814. Langues : Anglais (eng) in Autism Research > 14-8 (August 2021) . - p.1800-1814 Mots-clés : Adolescent  Antipsychotic Agents/adverse effects  Aripiprazole/adverse effects  Autism Spectrum Disorder/complications/drug therapy/epidemiology  Child  Cohort Studies  Female  Fractures, Bone/drug therapy/epidemiology  Humans  Male  Retrospective Studies  Risperidone/adverse effects  United States/epidemiology  antipsychotics  aripiprazole  autism spectrum disorder  fractures  risperidone Index. décimale : PER Périodiques Résumé : Risperidone and aripiprazole, commonly used antipsychotics in children with autism spectrum disorder (ASD), have previously been associated with elevated fracture risk in other populations. The aim of this study was to evaluate and compare the risk of fracture among children with ASD using risperidone or aripiprazole. This was a retrospective, propensity-score matched cohort study, set between January 2013 and December 2018. We used the MarketScan Medicaid insurance data, which covers multiple states of the United States. We included ASD children aged 2-18?years, who were new users of aripiprazole or risperidone and with no prior history of antipsychotic use or fractures. The main exposure was the continued use of aripiprazole or risperidone. The incidence rates of any fracture during follow-up were evaluated, and the risk between aripiprazole and risperidone was compared via Cox-proportional hazard models. Results were stratified by age, sex, duration of exposure and fracture site. In total, 3312 patients (78% male; mean [SD] age 11.0 [3.7] years) were identified for each cohort. Over the full duration of follow-up, fracture incidence rates per 1000 patient-years were 23.2 for risperidone and 38.4 for aripiprazole (hazard ratio and 95% confidence interval: 0.60 [0.44-0.83]). Risks were similar between cohorts throughout the first 180?days on treatment, but significantly higher in the aripiprazole group thereafter. Extremity fractures drove most of the increased risk, with the biggest differences in lower leg and ankle fractures. Differences widened for children aged 10?years or younger (HR [95% CI]: 0.47 [0.30-0.74]). In conclusion, compared to aripiprazole, risperidone was associated with 40% lower risk of fracture. Further analysis on the mechanism and long-term bone health of antipsychotic-treated children with ASD is warranted. LAY SUMMARY: We compared the risk of bone fractures among 6624 children with autism spectrum disorder (ASD), half of whom used risperidone and half of whom used aripiprazole. Taking other factors into account, risks were similar between the two groups throughout the first 180?days on treatment, but significantly higher in the aripiprazole group thereafter. The biggest differences were in lower leg and ankle fractures. Overall, compared with aripiprazole, risperidone was associated with 40% lower risk of fracture. En ligne : http://dx.doi.org/10.1002/aur.2541 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=449

Treatment patterns in children with autism in the United States / B. U. MONZ in Autism Research, 12-3 (March 2019)  

Permalink

---

1 (1 - 6 / 6)